[Sodium dichloroacetate--a substance with manifold therapeutic potential].
The therapeutic potential of sodium dichloroacetate (DCA) formerly called vitamin B 15, has already been under investigation for the past few years. The predominant property of DCA underlying its therapeutic action is activation of pyruvate dehydrogenase. The potential therapeutic use of DCA in the treatment of lactic acidosis and type II diabetes mellitus related directly to its stimulatory effect on this enzyme. Additional favourable effects of DCA on cardiac performance in states such as ischaemia, where glucose becomes a major energy-yielding substrate, have also been demonstrated. Treatment of lipid disorders might become further indications for the implementation of this substance. DCA inhibits hydroxy-methyl-glutaryl CoA reductase, thus lowering cholesterol and triglyceride levels. Earlier suggestions that DCA produced a major degree of acute toxicity were not confirmed in recent studies using DCA of established purity and homogeneity. These findings and recent evidence suggesting a potentially important role of DCA in the treatment of lactic acidosis are the reason and basis for a review of the established actions of this substance.